VACCINE FOR LEISHMANIASIS

描述：(改编自申请人摘要)申请人已克隆并 确定了利什曼病发生的三种候选抗原 疫苗。这三种抗原都是根据它们的诱导能力来选择的 保护性Th1反应。该提案建立在生成的支持性数据的基础上 在第一阶段研究期间，有可能实现这两个目标 重组人的预防性和治疗性保护性免疫应答 抗原，以及影响Th1/Th2应答图谱 利什曼病。在第二阶段建议期间，为 将会出现利什曼病。这将通过使用最好的 可用于实验性内脏和皮肤利什曼病的模型。抗原 实现持久保护的最佳组合将是 开发；也将选择可能用于人类的佐剂。它是 预计第一阶段IND将在第二阶段结束前提交 授权期。 建议的商业应用：不可用

DESCRIPTION: (Adapted from Applicant's Abstract) The applicants have cloned and characterized three candidate antigens for the development of a leishmaniasis vaccine. All three antigens were selected based on their ability to induce protective Thl responses. This proposal builds upon supportive data generated during the Phase I study period that it is possible to achieve both prophylactic and therapeutic protective immune responses using recombinant antigens, as well as to influence the Thl/Th2 response profile in leishmaniasis. During the Phase II proposal period a subunit vaccine for leishmaniasis will be developed. This will be accomplished by using the best available models for experimental visceral and cutaneous leishmaniasis. Antigen combinations that are optimal for achieving long lasting protection will be developed; adjuvants that may be used in humans will be selected as well. It is anticipated that a Phase I IND will be filed before the end of the Phase II grant period. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE